In general, up-to-date research indicates that medicinal cannabis does not cure diseases or disorders, but it can relieve symptoms associated with them or halt progression of a disease. In the period from 1975 to 2014, 142 randomised, double-blind, controlled clinical studies were published on herbal cannabis or pure cannabinoids. This represented 9,429 patients suffering from a wide range of medical conditions. Based on this wealth of data, it has been confirmed that cannabinoids exhibit therapeutic potential in the case of:
Alongside these conditions, cannabinoids show promising results in the symptomatic treatment of intestinal dysfunction, hyperactivity, anxiety disorders, allergies, and epilepsy.
Conventional medicine cannot sufficiently help many patients suffering from the above-mentioned diseases either because it is ineffective, or the side-effects are too severe.
Randomised, double-blind, and placebo-controlled clinical trials are the current gold standard for determining the efficacy and safety of medicines. Bedrocan is currently involved in such studies to help decide where and when treatment with cannabinoids is appropriate and responsible.
Severe chronic pain seems to be the major reason for which patients use cannabis medicinally. There are many types of pain, and cannabis does not influence each pain type identically. The therapeutic effects of cannabinoids seem to be most pronounced in neuropathic pain – the pain originating from injury or disease that affects the sensory nerves. Two prime examples of this disease type is multiple sclerosis (MS), where the patients’ nerves are attacked by their own immune system; and, fibromyalgia, where the nerves become hypersensitive and even a mild touch is perceived as painful. In contrast, studies measuring the effects on acute pain (e.g. postoperative pain) often show no beneficial effects of cannabis. Most likely, this difference is related to the role endocannabinoids play in both types of pain. However, the mechanism behind this difference is not yet fully understood.
Studies exploring patient therapeutic preferences indicate that for severe pain the majority of side-effects from cannabinoids are better tolerated than those from prolonged use of high doses of opioid medications. Chronic neuropathic pain is a common and difficult-to-treat symptom with limited treatment options. As a consequence, even modest therapeutic effects of cannabinoids may be relevant for suffering patients.
Because chronic pain is difficult to treat with any single medicine, cannabinoids have often been studied in combination with other therapeutics, including strong opioids such as morphine. It was found that cannabinoids and opioids work together with a strong combined effect. This effect is called ‘synergy’. As a result, the addition of cannabinoids can often result in a lowering of the opioid dose in a patient’s daily drug regimen. Dual therapies have been seen to reduce the unwanted mild to severe side-effects of opioids, for example, nausea and vomiting, tolerance, sedation and respiratory depression.
Together with chronic pain, multiple sclerosis (MS) is the other medical condition in which long-term effects of cannabinoids have been studied extensively (mainly in the form of the pharmaceutical product Sativex®). The studies show patients do not develop a tolerance for the medicinal effects, nor do they increase their doses over time to achieve the same therapeutic result. Although the medical evidence supporting cannabis use for MS is still limited, it is important to note the same is true for most conventional MS medications.
Numerous patients worldwide currently use cannabis and cannabinoids to alleviate pain, muscle spasms, or cramps associated with MS or spinal cord damage. Indeed, the majority of clinical trials with cannabinoid-based medicines have focused on MS. Standard therapy often provides inadequate relief and can be limited by medication side-effects. Consequently, patients suffering from MS have historically experimented with alternative therapies, including cannabis, to improve their quality of life. Nowadays, scientific evidence exists supporting the beneficial effects of cannabinoids on disease-related pain, bladder symptoms, tremor, and spasticity. Additionally, sleep improves significantly by using cannabinoids, resulting in both deeper and longer sleep.
Cannabis can have strong effects on nausea and vomiting resulting from cancer chemotherapy or radiotherapy treatment, hepatitis C, HIV infection or AIDS. Since 1986, synthetic THC (as Marinol®) has been approved by the US Food and Drug Administration (FDA) as an appetite stimulant in the case of anorexia associated with weight loss in patients with HIV/AIDS. Marinol® has also been approved as an antiemetic for cancer patients undergoing chemotherapy. Supporting studies suggest that the addition of THC directly before and after chemotherapy offer more benefit than conventional antiemetic medications alone.
Cannabis has been shown to stimulate appetite, described as a strong desire for foods with high fat or sugar content. For these patients, a high caloric intake may contribute to weight gain and to the absorption of nutrients, often crucial in combating medical conditions such as AIDS-related wasting syndrome.
Although other drugs are available to treat nausea, vomiting, or reduced appetite, the combined effect of cannabis on all these symptoms at once makes it a particularly potent drug for improving a patient’s quality of life. For patients suffering from nausea or vomiting, often oral medications are inconvenient. For these patients, administration via inhalation – using a vaporization medical device – reduces the burden of oral medication and achieves therapeutic levels rapidly.
Tourette syndrome is a neuropsychiatric disorder, characterised by physical (motor) and vocal (phonic) tics. Anecdotal reports provide some evidence that cannabis is effective not only in the suppression of such tics, but also in the treatment of associated behavioural disorders such as obsessive-compulsive behaviour. Clinical trials investigating the effect of (pure) THC in the treatment of Tourette syndrome showed a significant tic reduction without causing significant adverse effects. Because the highly visible tics have an enormous impact on Tourette patients’ social lives, even a small effect of cannabis could be considered relevant. THC may, therefore, be a promising treatment of Tourette syndrome in adult patients, when first-line treatments failed to reduce the tics.
In glaucoma patients, a progressive increase of pressure inside the eye causes a gradual loss of vision, resulting in total blindness if untreated. Studies in the 1970s showed cannabis, when inhaled or eaten, effectively lowers eye pressure as much as standard medications.
Although currently many treatment options are available, glaucoma is still one of the leading causes of irreversible blindness worldwide. Cannabis may, therefore, be a promising treatment when conventional treatments do not produce the desired effects. However, the duration of the pressure-lowering effect is typically in the range of several hours. Therefore, cannabis medicine would require dosing at regular intervals.
Outside the care of their doctors, patients self-medicate with cannabis for a wide range of medical conditions. Based on the available scientific evidence, further attention should be focused on three other potential uses of medicinal cannabis including the treatment of cancer, epilepsy, and psychiatric disorders.
Cannabinoids exert palliative effects in cancer patients by reducing nausea, vomiting and pain, by stimulating appetite, and by improving the quality of sleep. However, laboratory studies in animals and isolated cancer cells have shown cannabinoids to be capable, under some conditions, of inhibiting the development of cancer cells in multiple ways.
As a result of such exciting findings, a growing number of non-scientific accounts have appeared on the internet claiming cannabis to be a cure for cancer. Nevertheless, in spite of on-going research, there is currently no solid evidence from clinical trials to support such claims.
It should be noted, however, that the potential effects of terpenes on cancer, either alone or in combination with cannabinoids, are yet to be addressed in laboratory studies. Indeed, the combined effects of cannabinoids and terpenes are often claimed to be the major difference between ‘holistic’ herbal preparations of cannabis and pharmaceutical products based on single cannabinoids. However, the exact nature of the effects of cannabinoid-terpene combinations has not yet been studied.
Moreover, extraction methods and/or administration forms used by self-medicating patients often differ from those used in laboratory or hospital studies. Because of this gap between real-life experiences and clinical research, the curative potential of herbal cannabis preparations for the treatment of different cancer types remains unclear.
Although epilepsy may be well-controlled by existing medications, a significant number of people with epilepsy do not have adequate control of their seizures. Although surgery may be considered for difficult cases, this is a delicate, complicated operation with great risk to a patient’s brain. Therefore, in treatment-resistant patients, the use of cannabis may seem a viable alternative. As early as in 1979, studies on rats confirmed the anticonvulsant effects of (pure) CBD. In various subsequent animal and (small-scale) human studies, CBD was able to reduce the frequency and severity of seizures. Combined with an absence of psychoactive effects, these results show the potential of CBD as a therapeutic candidate for human epilepsies.
Another upcoming, but only partially understood, application of cannabinoids is in the treatment of psychiatric disorders such as schizophrenia, anxiety and bipolar disorder. Although long-term consumption of high doses of THC is a potential risk factor for the development of mental illnesses, other cannabinoids seem to have the reverse effect. In particular, the non-psychoactive cannabinoid CBD has shown potential in the treatment of anxiety and different types of psychosis, like schizophrenia. In a study using pure CBD, it was found to have substantial antipsychotic properties in acute schizophrenia, with an efficacy comparable to the standard drugs. Currently, high CBD cannabis varieties are being developed to respond to the increasing demand for these substances.